Skye Bioscience, Inc. Receives Nasdaq Deficiency Notice: What Investors Need to Know
Key Points:
- Skye Bioscience, Inc. (Nasdaq: SKYE) has received a deficiency letter from the Nasdaq Stock Market LLC, signaling that the company has failed to maintain the minimum bid price requirement for continued listing on the Nasdaq Global Market.
- The closing bid price of SKYE’s common stock has been below \$1.00 for the past 30 consecutive business days, triggering the notice under Nasdaq Listing Rule 5450(a)(1).
- This deficiency notice does not have an immediate effect on the listing status of Skye’s common stock, which will continue to trade under the symbol “SKYE” for now.
Detailed Analysis:
On March 17, 2026, Skye Bioscience, Inc. disclosed that it received a formal deficiency letter from the Nasdaq Listing Qualifications Department. The issue arose because the company’s common stock traded below the critical \$1.00 per share threshold for 30 consecutive business days, a requirement for continued listing on the Nasdaq Global Market.
According to the Nasdaq rules, Skye now has 180 calendar days (until September 14, 2026) to regain compliance with the minimum bid price standard. The company can regain compliance if the closing bid price for its common stock meets or exceeds \$1.00 per share for at least 10 consecutive business days during this period.
If Skye fails to meet the requirement by the deadline, it may be eligible for a second 180-day compliance period. To qualify for this extension, Skye must meet all other initial listing standards for the Nasdaq Capital Market (excluding the minimum bid price). Additionally, the company must notify Nasdaq of its plan to cure the deficiency, which could include measures such as a reverse stock split. If a reverse stock split is chosen, it must be completed no later than ten business days prior to the end of the compliance period.
The company stated it intends to monitor its share price actively and consider all available options to resolve the deficiency. However, the filing cautioned that there can be no assurance that Skye will regain compliance with the rule or fulfill other Nasdaq listing requirements.
Potential Impact for Shareholders:
- This notice is a material event that could impact investor sentiment and share price.
- Failure to regain compliance may result in Skye’s common stock being transferred to the Nasdaq Capital Market or delisted entirely, which could significantly affect liquidity and the company’s visibility in capital markets.
- Shareholders should be aware that potential solutions, such as a reverse stock split, could change the number of shares outstanding and impact share price dynamics.
- The company’s ongoing eligibility for Nasdaq listing is now at risk, making this a price-sensitive development.
Corporate Information:
- Registrant: Skye Bioscience, Inc.
- State of Incorporation: Nevada
- Business Address: 11250 El Camino Real, Suite 100, San Diego, CA 92130
- CEO: Punit Dhillon
- Trading Symbol: SKYE
- Exchange: Nasdaq Global Market
Shareholders and investors are strongly advised to monitor future disclosures from Skye Bioscience, as any progress or lack thereof regarding compliance could result in significant share price movements.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Please consult your financial advisor before making any investment decisions. The information is based on regulatory filings as of March 2026 and may be subject to change.
View Skye Bioscience, Inc. Historical chart here
